CovidX aspires to investigate whether a food supplement based on a novel Spirulina extract can strengthen the immune system and help reduce infection risk of SARS-CoV-2 infection. The supplement will not be a replacement for SARS-SoV-2 vaccinations.
Aqueous Spirulina extract is already approved for use in food in the US and EU with no toxicity limitations or known allergens. It has unique advantages, including bio-security, consistent quality and taste and is high in bioactive compounds. The aim of the food supplement is to develop a natural shield to high-risk population groups such as the elderly and people with severe underlying medical conditions, as well as high-exposure groups e.g. medical personnel, however the supplement will not be a replacement for SARS-CoV-2 vaccinations.
As part of the EIT’s Crisis Response Initiative, this activity directly contributes to the European Union’s response to the COVID-19 pandemic.